Conestat Alfa (a Recombinant Human C1 Esterase Inhibitor) for the Prevention of Acute Kidney Injury After Non-ST Elevation Myocardial Infarction: a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2, Dose-finding Study
A randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in patients with NSTEMI undergoing urgent coronary angiography. Approximately 220 patients with CKD and acute NSTEMI, who are scheduled for an urgent coronary angiography (within 72 hours after admission and/or diagnosis of NSTEMI).
Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).
The main objective of this study is to evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections.
开始日期2021-02-04
申办/合作机构-
100 项与 C1S x Kallikreins x 甘露糖结合凝集素相关丝氨酸蛋白酶 相关的临床结果
登录后查看更多信息
100 项与 C1S x Kallikreins x 甘露糖结合凝集素相关丝氨酸蛋白酶 相关的转化医学
登录后查看更多信息
0 项与 C1S x Kallikreins x 甘露糖结合凝集素相关丝氨酸蛋白酶 相关的专利(医药)